Reteplase

Reteplase
Clinical data
Trade names	Retavase, Retefuse, Rapilysin,Mirel, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
ATC code	B01AD07 (WHO) ;
Identifiers
CAS Number	133652-38-7 ;
DrugBank	DB00015 ;
ChemSpider	none;
UNII	DQA630RIE9;
KEGG	D05721 ;
Chemical and physical data
Formula	C1736H2671N499O522S22
Molar mass	39589.75 g·mol−1
	(verify)

Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.^{[citation needed]} Reteplase was approved for use in 1996.^[1]

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.

References

^ Mohammadi E, Seyedhosseini-Ghaheh H, Mahnam K, Jahanian-Najafabadi A, Mir Mohammad Sadeghi H (2019). "Reteplase: Structure, Function, and Production". Advanced Biomedical Research. 8: 19. doi:10.4103/abr.abr_169_18. PMC 6446582. PMID 31016177.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[Mohammadi-1] Mohammadi E, Seyedhosseini-Ghaheh H, Mahnam K, Jahanian-Najafabadi A, Mir Mohammad Sadeghi H (2019). "Reteplase: Structure, Function, and Production". Advanced Biomedical Research. 8: 19. doi:10.4103/abr.abr_169_18. PMC 6446582. PMID 31016177.

[1]